Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
A phase 2 trial of Naporafenib, Trametinib, Ribociclib in melanoma, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma is a phase 2 interventional study registered as NCT04417621 by Novartis Pharmaceuticals, with 134 participants enrolled, started 2020-10-30 and due to reach its primary completion in 2027-02-02. Interventions recorded: LXH254, LTT462, Trametinib, Ribociclib. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Shares Naporafenib, Melanoma.
- TrialPlatform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Shares Trametinib, Ribociclib, Novartis.
- TrialStudy of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto
Shares Trametinib, Novartis.
- TrialStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Shares Ribociclib, Novartis.
- TrialRollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other
Shares Trametinib, Novartis.
- TrialCOMBI-AD
Shares Trametinib, Melanoma.
- TreatmentADU-S100 (MIW815)
- TreatmentDabrafenib
Shares Trametinib, Novartis, Melanoma.